MiMedx Capital Surpluse from 2010 to 2025

MDXG Stock  USD 8.40  0.26  3.19%   
MiMedx's Capital Surpluse is increasing over the last several years with slightly volatile swings. Capital Surpluse is predicted to flatten to about 157.7 M. During the period from 2010 to 2025 MiMedx Group Capital Surpluse regressed destribution of quarterly values had coefficient of variationof  23.90 and r-value of  0.74. View All Fundamentals
 
Capital Surpluse  
First Reported
2011-06-30
Previous Quarter
178.8 M
Current Value
182.9 M
Quarterly Volatility
32.5 M
 
Yuan Drop
 
Covid
Check MiMedx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MiMedx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 1.8 M or Selling General Administrative of 129.7 M, as well as many indicators such as Price To Sales Ratio of 3.85, Dividend Yield of 0.0 or PTB Ratio of 6.96. MiMedx financial statements analysis is a perfect complement when working with MiMedx Valuation or Volatility modules.
  
Check out the analysis of MiMedx Correlation against competitors.

Latest MiMedx's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of MiMedx Group over the last few years. It is MiMedx's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MiMedx's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

MiMedx Capital Surpluse Regression Statistics

Arithmetic Mean147,010,431
Geometric Mean141,784,405
Coefficient Of Variation23.90
Mean Deviation25,458,310
Median162,433,000
Standard Deviation35,132,675
Sample Variance1234.3T
Range116.7M
R-Value0.74
Mean Square Error589.7T
R-Squared0.55
Significance0.0009
Slope5,493,090
Total Sum of Squares18514.6T

MiMedx Capital Surpluse History

2025157.7 M
2024190.5 M
2021165.7 M
2020158.6 M
2019147.2 M
2017164.7 M
2016161.3 M

About MiMedx Financial Statements

MiMedx stakeholders use historical fundamental indicators, such as MiMedx's Capital Surpluse, to determine how well the company is positioned to perform in the future. Although MiMedx investors may analyze each financial statement separately, they are all interrelated. For example, changes in MiMedx's assets and liabilities are reflected in the revenues and expenses on MiMedx's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MiMedx Group. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse190.5 M157.7 M

Currently Active Assets on Macroaxis

When determining whether MiMedx Group is a strong investment it is important to analyze MiMedx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact MiMedx's future performance. For an informed investment choice regarding MiMedx Stock, refer to the following important reports:
Check out the analysis of MiMedx Correlation against competitors.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MiMedx. If investors know MiMedx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MiMedx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.86)
Earnings Share
0.28
Revenue Per Share
2.374
Quarterly Revenue Growth
0.07
Return On Assets
0.1474
The market value of MiMedx Group is measured differently than its book value, which is the value of MiMedx that is recorded on the company's balance sheet. Investors also form their own opinion of MiMedx's value that differs from its market value or its book value, called intrinsic value, which is MiMedx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MiMedx's market value can be influenced by many factors that don't directly affect MiMedx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MiMedx's value and its price as these two are different measures arrived at by different means. Investors typically determine if MiMedx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MiMedx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.